Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFI8A7)

• Drug Name: Tranexamic Acid Drug Info
• Synonyms: AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Excessive bleeding	GA30.02	Approved	[1]
Menorrhagia	GA20.50	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
Endometriosis	GA10	Investigative	[2]

• Therapeutic Class: Antifibrinolytic Agents
• Cross-matching ID:
  PubChem CID: 5526
  ChEBI ID: CHEBI:48669
  CAS Number: CAS 701-54-2
  TTD Drug ID: DMFI8A7
  ACDINA Drug ID: D00696

Molecule-Related Drug Atlas

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[5]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[6]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[7]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[8]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[8]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[9]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[10]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[11]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[12]
Plasminogen	DM0EFQS	Alzheimer disease	8A20	Phase 2/3	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6573).
• [2] Tranexamic acid FDA Label
• [3] Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients (TCInpatient)
• [4] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [5] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [6] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [7] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [8] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [9] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [10] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [11] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [12] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
• [13] Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.